Document Detail

Safety and Efficacy of Prasugrel Use in Patients Undergoing Percutaneous Coronary Intervention and Anticoagulated With Bivalirudin.
MedLine Citation:
PMID:  23219177     Owner:  NLM     Status:  Publisher    
The randomized TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction (TRITON-TIMI) 38 trial compared prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI). Patients treated with prasugrel had fewer ischemic events but more procedure-related bleeding. In the present study, we aimed to determine the effect of bivalirudin on bleeding in patients treated with prasugrel. A total of 692 patients with consecutive acute coronary syndrome underwent PCI with stent implantation and were anticoagulated with bivalirudin. The patients were divided into 2 groups according to the antiplatelet regimen (clopidogrel or prasugrel) chosen during or just after PCI. The bleeding complications during hospitalization were tabulated. Ischemic events were analyzed during hospitalization and at 30 days. Prasugrel was used in 96 patients (13.9%) and clopidogrel in 596 (86.1%). The clinical and procedural characteristics were similar, although the clopidogrel patients more often reported systemic hypertension (p = 0.01), previous PCI (p <0.001), and chronic renal insufficiency (p = 0.05). During hospitalization, the bleeding and ischemic complication rates were similar and low in both groups (major in-hospital complications 4.2% for clopidogrel vs 2.1% for prasugrel, p = 0.6; Thrombolysis In Myocardial Infarction major bleeding 2.5% vs 2.1%, p = 1.00; Thrombolysis In Myocardial Infarction minor bleeding 4.2% vs 5.2%, p = 0.6). At 30 days, no differences were found in ischemic events between both groups (target vessel revascularization/major adverse cardiac events 5.4% vs 2.1%, p = 0.2). In conclusion, prasugrel, when given after bivalirudin as the intraprocedural antithrombin agent for patients with acute coronary syndrome undergoing PCI, is as safe and effective as clopidogrel.
Ana Laynez; Gabriel Sardi; Rebecca Torguson; Zhenyi Xue; William O Suddath; Lowell F Satler; Kenneth M Kent; Augusto D Pichard; Joseph Lindsay; Ron Waksman
Related Documents :
15534077 - Systolic blood pressure during recovery from exercise and the risk of acute myocardial ...
8780267 - Alterations of cardiovascular performance during laparoscopic colectomy: a combined hem...
11061397 - Coronary angiography and coronary artery revascularisation rates in public and private ...
25086257 - Early cerebral thromboembolic complications following radiofrequency catheter ablation ...
9205847 - When, and when not, to use digoxin in the elderly.
16480007 - Results of concomitant aortic valve replacement and coronary artery bypass grafting in ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-12-4
Journal Detail:
Title:  The American journal of cardiology     Volume:  -     ISSN:  1879-1913     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2013 Elsevier Inc. All rights reserved.
Division of Cardiology, Department of Internal Medicine, MedStar Washington Hospital Center, Washington, DC.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Usefulness of cardiac biomarker score for risk stratification in stable patients undergoing elective...
Next Document:  Effect of ezetimibe on major atherosclerotic disease events and all-cause mortality.